This is a working overview of NMNAT, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-29 and is reviewed periodically as new material appears.
Quality control for NMN focuses on identity, purity, and the absence of harmful contaminants. Certificates of analysis may report high-performance liquid chromatography purity, mass spectrometry identity, residual solvents, heavy metals, and microbial limits, depending on grade and intended use. Because NMN can exist as different isomers, salts, or hydrates, specification sheets should state the exact form being tested. There is no single globally harmonized purity standard for NMN products. Open questions include which degradation products are most relevant under real-world storage and how analytical results from different laboratories can be compared reliably.
Analytical measurement of NMN typically uses reversed-phase high-performance liquid chromatography with ultraviolet detection near 260 nm. Mass spectrometry, often coupled to liquid chromatography, provides sensitive quantification and confirmatory identification in biological matrices. Nuclear magnetic resonance spectroscopy is used to verify molecular structure and distinguish related nucleotides. Because NMN is polar and poorly retained on conventional reversed-phase columns, ion-pairing reagents or hydrophilic interaction chromatography are sometimes employed. Reported purity values depend on the chosen method, calibration standard, and whether related substances are resolved.
Stability studies indicate that NMN is sensitive to heat, light, and pH extremes. In aqueous solution, hydrolysis can cleave the phosphate linkage or convert NMN to related nicotinamide derivatives, with degradation accelerating at elevated temperatures and alkaline conditions. Solid material is generally more stable when kept dry and cold, and research-grade supplies are often stored at minus twenty degrees Celsius or lower, protected from light and moisture. Repeated freeze-thaw cycles of solutions can promote degradation, so aliquoting is a common laboratory practice. The exact shelf life depends on purity, counterion, packaging, and storage history.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
| Property | Value | Notes |
|---|---|---|
| Typical purity assay | HPLC-UV or LC-MS | Purity may be reported as area percent or weight percent. |
| Identification methods | NMR, high-resolution MS, UV spectroscopy | Used together for structural confirmation. |
| Storage temperature | -20 °C or below, desiccated | Limits hydrolysis and microbial growth. |
| Light sensitivity | Protect from light | Amber glass or opaque containers reduce photodegradation. |
| Common synonyms | Nicotinamide mononucleotide, beta-NMN, NMN | Synonym use varies by isomer and salt form. |
Quality control for NMN materials typically includes identity, assay, impurity, and residual solvent tests. Certificates of analysis may report HPLC purity, water content, heavy metals, and microbial limits depending on the intended use. Because commercial NMN is sold as a research chemical or ingredient rather than a standardized drug in many jurisdictions, specifications can vary between suppliers. Independent verification can involve comparing retention time, mass spectrum, and NMR data against a reference standard. Open questions remain about how best to standardize purity claims and biological potency across different production methods.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally considered hygroscopic and may degrade faster in aqueous solution than in dry powder form. Phosphate esters can hydrolyze under strongly acidic or alkaline conditions, and elevated temperatures accelerate such reactions. For storage, sealed containers at low temperature with desiccant are typical laboratory practices. Stability-indicating methods should separate NMN from its degradation products, including nicotinamide and nicotinamide riboside, so that purity loss can be tracked accurately.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
NMN is a polar, water-soluble nucleotide. In solid form it is usually a white to off-white powder. The compound is sensitive to heat, light, moisture, and extremes of pH, and aqueous solutions tend to degrade faster than dry material. Recommended storage for research samples is typically -20 °C or below in a sealed, desiccated container protected from light. Repeated freeze-thaw cycles should be avoided, and these handling practices help maintain identity and purity during laboratory use.
Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. As an intermediate in the NAD+ salvage pathway, NMN is converted to nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. NAD+ also serves as a substrate for enzymes involved in DNA repair, stress responses, and metabolic regulation. The compound is therefore part of normal cellular biochemistry rather than an exclusively synthetic molecule.
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
Arrestins block GPCR coupling to G proteins in two ways. First, arrestin binding to the cytoplasmic face of the receptor occludes the binding site for heterotrimeric G-protein, preventing its activation (desensitization). Second, arrestin links the receptor to elements of the internalization machinery, clathrin and clathrin adaptor AP2, which promotes receptor internalization via coated pits and subsequent transport to internal compartments, called endosomes. Subsequently, the receptor could be either directed to degradation compartments (lysosomes) or recycled back to the plasma membrane where it can again signal. The strength of arrestin-receptor interaction plays a role in this choice: tighter complexes tend to increase the probability of receptor degradation (Class B), whereas more transient complexes favor recycling (Class A), although this rule is far from absolute. More recently direct interactions between Gi/o family G proteins and Arrestin were discovered downstream of multiple receptors, regardless of canonical G protein coupling. These recent findings introduce a GPCR signaling mechanism distinct from canonical G protein activation and β-arrestin desensitization in which GPCRs cause the formation of Gαi:β-arrestin signaling complexes.
Camurus aims to collaborate with biotechnology and pharmaceutical companies worldwide to enable and improve the delivery of a wide range of drug compounds. These compounds including peptides, proteins, and insoluble small molecules make use of delivery solutions ranging from long-acting depots to lipid nanocarriers designed for improved intravenous, transdermal, and oral delivery. Camurus' in-house product portfolio targets healthcare needs in areas of growth-hormone disorders, cancer, oncology supportive care, metabolic disease, and drug addiction. In 2007, British investors evaluated six nominated private companies and chose to Camurus as the best privately owned biotechnology company in the Medicon Valley. The company was awarded the Strictly Financing Award 2007. In 2013, Camurus was awarded CPhI Pharma Award for Best Innovation in Formulation.
Topical analgesia is generally recommended to avoid systemic side-effects. Painful joints, for example, may be treated with an ibuprofen- or diclofenac-containing gel (The labeling for topical diclofenac has been updated to warn about drug-induced hepatotoxicity.); capsaicin also is used topically. Lidocaine, an anesthetic, and steroids may be injected into joints for longer-term pain relief. Lidocaine is also used for painful mouth sores and to numb areas for dental work and minor medical procedures. In February 2007 the FDA notified consumers and healthcare professionals of the potential hazards of topical anesthetics entering the bloodstream when applied in large doses to the skin without medical supervision. These topical anesthetics contain anesthetic drugs such as lidocaine, tetracaine, benzocaine, and prilocaine in a cream, ointment, or gel.
Autosomal-dominant mutations in APP cause hereditary early-onset Alzheimer's disease (familial AD, fAD). This form of AD accounts for no more than 10% of all cases, and the vast majority of AD is not accompanied by such mutations. However, familial Alzheimer's disease is likely to result from altered proteolytic processing. This is evidenced by the fact that many mutations that lead to fAD occur near γ-secretase cleavage sites on APP. One of the most common mutations causing fAD, London Mutation, occurs at codon 717 of the APP gene, and results in a valine to isoleucine amino acid substitution. Histochemical analysis of the APP V717I mutation has revealed extensive Aβ pathology throughout neuroaxis as well as widespread cerebral amyloid angiopathy (CAA). The gene for the amyloid precursor protein is located on chromosome 21, and accordingly people with Down syndrome have a very high incidence of Alzheimer's disease.
Cilengitide, a cyclic pentapeptide (RGDfV), is an investigational drug intended to block the growth of new blood vessels in tumors by interfering with the activation of integrin αVβ3. This integrin is upregulated in tumor and activated endothelial cells. This and other anti-angiogenic therapies depend on cutting off the blood supply to the tumor micro-environment, leading to hypoxia and necrosis. Cilengitide has been evaluated for the treatment of glioblastoma, but, as is the case for other anti-angiogenic therapies, has not been shown to alter progression or improve survival either alone or in combination with standard treatments. CEND-1, also known as iRGD, is a cyclic peptide that homes to tumors via binding to integrin alpha V receptors. It also binds and activates neuropilin-1, leading to a temporary opening of the tumor and an enhanced delivery of anti-cancer agents into the tumor tissue. It is currently being tested in clinical trials in solid tumor patients.
Sources: en.wikipedia.org
Adrenocorticotropic hormone (ACTH; also adrenocorticotropin, corticotropin) is a polypeptide tropic hormone produced by and secreted by the anterior pituitary gland. It is also used as a medication and diagnostic agent. ACTH is an important component of the hypothalamic-pituitary-adrenal axis and is often produced in response to biological stress (along with its precursor corticotropin-releasing hormone from the hypothalamus). Its principal effects are increased production and release of cortisol and androgens by the zona fasciculata and zona reticularis, respectively. ACTH is also related to the circadian rhythm in many organisms. Deficiency of ACTH is an indicator of secondary adrenal insufficiency (suppressed production of ACTH due to an impairment of the pituitary gland or hypothalamus, cf. hypopituitarism) or tertiary adrenal insufficiency (disease of the hypothalamus, with a decrease in the release of corticotropin releasing hormone (CRH)). Conversely, chronically elevated ACTH levels occur in primary adrenal insufficiency (e.g. Addison's disease) when adrenal gland production of cortisol is chronically deficient. In Cushing's disease, a pituitary tumor leads to excessive production of ACTH, which stimulates the adrenal cortex to produce high levels of cortisol.
In both pharmacology and nutrition sciences, bioavailability is measured by calculating the area under curve (AUC) of the drug concentration time profile. Bioavailability is a term used to describe the percentage of an administered dose of a xenobiotic that reaches the systemic circulation unchanged. It is denoted by the letter f (or, if expressed in percent, by F). In nutritional science, which covers the intake of nutrients and non-drug dietary ingredients, the concept of bioavailability lacks the well-defined standards associated with the pharmaceutical industry. The pharmacological definition cannot apply to these substances because utilization and absorption is a function of the nutritional status and physiological state of the subject, resulting in even greater differences from individual to individual (inter-individual variation). Therefore, bioavailability for dietary supplements can be defined as the proportion of the administered substance capable of being absorbed and available for use or storage.
The presentation of amyloidosis is broad and depends on the site of amyloid accumulation. The kidney and heart are the most common organs involved. Amyloid deposition in the kidney often involve the glomerular capillaries and mesangial regions, affecting the organ's ability to filter and excrete waste and retain plasma protein. This can lead to high levels of protein in the urine (proteinuria) and nephrotic syndrome. Several types of amyloidosis, including the AL and AA types, are associated with nephrotic syndrome. Approximately 20% and 40–60% of people with AL and AA amyloidosis respectively progress to end-stage kidney disease requiring dialysis.
Vasoactive intestinal peptide (VIP) is a 28-residue amino acid peptide first characterized in 1970 that was initially isolated from porcine duodenum. A member of the secretin/glucagon hormone superfamily, VIP was initially discovered owing to its potent vasodilatory effects (as its name implies). VIP is widely distributed in the central and peripheral nervous system as well as in the digestive, respiratory, reproductive, and cardiovascular systems as a neurotransmitter and neuroendocrine releasing factor. These effects contribute to an extensive range of physiological and pathological processes related to development, growth, and the control of neuronal, epithelial, and endocrine cell function. VIP acts on two receptors - VPAC1 and VPAC2, which are class B of G-protein-coupled receptors (GPCRs).VPAC1 is mainly present in the lung and T-lymphocytes, whereas VPAC2 is mainly seen in the smooth muscle, mast cells and the basal parts of the lung mucosa.
The PAH world hypothesis is a speculative hypothesis that proposes that polycyclic aromatic hydrocarbons (PAHs), known to be abundant in the universe, including in comets, and assumed to be abundant in the primordial soup of the early Earth, played a major role in the origin of life by mediating the synthesis of RNA molecules, leading into the RNA world. However, as yet, the hypothesis is untested.
Sources: en.wikipedia.org
Liquid chromatography coupled with tandem mass spectrometry is widely used because it can separate NMN from related nucleotides and quantify low concentrations. Stable isotope-labeled internal standards help correct for matrix effects and recovery losses. Ultraviolet detection alone is less specific for complex biological matrices.
Research-grade NMN powder is commonly stored frozen, desiccated, and protected from light. Sealed containers at minus twenty degrees Celsius or below are typical. Allow containers to reach room temperature before opening to reduce condensation.
Purity is one quality attribute and does not by itself establish identity, safety, or absence of contaminants. A complete assessment includes structural confirmation, residual solvent testing, and microbial limits when relevant. Different analytical methods can yield different purity values.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.